2023 World Conference on Lung Cancer (Posters)-P2.17. CAN: A Phase II Trial of Combination of Niraparib and Anlotinib in Patients with Recurrent Small Cell Lung Cancer

P2.17. CAN: A Phase II Trial of Combination of Niraparib and Anlotinib in Patients with Recurrent Small Cell Lung Cancer - PDF(Abstract)

Back to course

Pdf Summary

In this study presented at the WCLC 2023 conference, researchers investigated the efficacy and safety of combining Niraparib and Anlotinib in treating recurrent small cell lung cancer (SCLC). SCLC is associated with a poor prognosis and limited treatment options, resulting in a median overall survival of around 26 weeks for recurrent cases. The CAN study is a phase II trial that enrolled patients with confirmed recurrent SCLC who had received platinum-based chemotherapy. They received Niraparib and Anlotinib for a 21-day cycle and continued treatment until disease progression, unacceptable toxicity, death, or withdrawal of informed consent. The primary endpoint was overall response rate (ORR), with secondary endpoints including progression-free survival (PFS), overall survival (OS), disease control rate (DCR), duration of response (DOR), and safety. <br /><br />As of January 31, 2023, the study had met the criteria for entering the second stage of enrollment. Twenty-five patients were enrolled, with a median age of 63 and all patients having an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 1. Sixty percent of patients had a smoking history, and baseline evaluations showed bone metastasis in 16% of patients and brain metastasis in 28%. The median previous systematic treatment was 1, with 32% of patients having received immunotherapy. Of the 20 evaluable patients, the confirmed ORR was 20%, with 4 partial responses (PR) and 4 stable disease (SD). Two patients had unconfirmed PR due to Covid-19 pandemic and intolerance, resulting in an unconfirmed ORR of 30%. The median duration of response was 4.3 months. The median PFS was 7.06 months, and median OS was not reached. The serious adverse event rate was 20%, with the most common serious adverse events being hematology-related, such as anemia and lymphopenia. Three patients died during serious adverse events, likely due to disease progression rather than drug-related reasons. <br /><br />Overall, combining Niraparib with Anlotinib showed potential efficacy and good tolerance in treating recurrent SCLC. The study is still ongoing with the second stage of enrollment.

Asset Subtitle

Ying Cheng

Meta Tag

Speaker Ying Cheng

Topic SCLC & Neuroendocrine Tumors: Relapse & Salvage Therapy

Keywords

Niraparib

Anlotinib

small cell lung cancer

SCLC

recurrent

efficacy

safety

phase II trial

overall response rate

progression-free survival